Indonesia to co-produce Chinese Covid-19 vaccine
In addition to developing its own Covid-19 vaccine, Indonesia entered an agreement on August 20 with Chinese biotech company Sinovac to receive up to 40 million doses of a coronavirus vaccine to the county starting in November.
The agreement was signed between Sinovac and Indonesia’s PT Bio Farma, according to Indonesia’s foreign minister Retno Marsudi.
Indonesia has already been conducting final phase three testing with support from PT Bio Pharma and a team of Indonesian scientists and researchers.
Once clinical testing is completed, massive vaccine production will begin immediately at PT Bio Farma’s laboratories and is expected to reach a level of 250 million doses annually, paving the way to reaching immunity within the population.
Other pharma firms targeted for cooperation in vaccine development
There are further discussion with other Chinese pharmaceutical companies, including Sinopharm and CanSino Biologics over possible cooperations in developing Covid-19 vaccines.
Retno said Indonesia is also in talks with other pharma firms outside China, namely in South Korea, in efforts to get enough vaccine for Indonesia’s 270 million people amid tough competition for supplies.
As of August 22, Indonesia reported more than 151,000 cases, the second largest number in Southeast Asia behind the Philippines. The death toll so far is 6,594, with around 105,000 infected people recovered.
In addition to developing its own Covid-19 vaccine, Indonesia entered an agreement on August 20 with Chinese biotech company Sinovac to receive up to 40 million doses of a coronavirus vaccine to the county starting in November. The agreement was signed between Sinovac and Indonesia’s PT Bio Farma, according to Indonesia’s foreign minister Retno Marsudi. Indonesia has already been conducting final phase three testing with support from PT Bio Pharma and a team of Indonesian scientists and researchers. Once clinical testing is completed, massive vaccine production will begin immediately at PT Bio Farma’s laboratories and is expected to reach a...
In addition to developing its own Covid-19 vaccine, Indonesia entered an agreement on August 20 with Chinese biotech company Sinovac to receive up to 40 million doses of a coronavirus vaccine to the county starting in November.
The agreement was signed between Sinovac and Indonesia’s PT Bio Farma, according to Indonesia’s foreign minister Retno Marsudi.
Indonesia has already been conducting final phase three testing with support from PT Bio Pharma and a team of Indonesian scientists and researchers.
Once clinical testing is completed, massive vaccine production will begin immediately at PT Bio Farma’s laboratories and is expected to reach a level of 250 million doses annually, paving the way to reaching immunity within the population.
Other pharma firms targeted for cooperation in vaccine development
There are further discussion with other Chinese pharmaceutical companies, including Sinopharm and CanSino Biologics over possible cooperations in developing Covid-19 vaccines.
Retno said Indonesia is also in talks with other pharma firms outside China, namely in South Korea, in efforts to get enough vaccine for Indonesia’s 270 million people amid tough competition for supplies.
As of August 22, Indonesia reported more than 151,000 cases, the second largest number in Southeast Asia behind the Philippines. The death toll so far is 6,594, with around 105,000 infected people recovered.
